Trials: Focal Onset Seizures

Phase 4 N=52 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

Partial Epilepsy

Primary: Change in Epworth Sleepiness Scale Score From Baseline to Visit 4 — -1.2; -1.1 Units on a scale — p=0.027

The Cleveland Clinic Results Dec 2016 5.8% serious AE View details

Phase 2 N=154 A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

Primary: Response Ratio (RRatio) — -24.06; -22.45; -25.90; -24.19 RRatio — p==0.986

AbbVie Results May 2025 4.6% serious AE View details

Phase 3 N=17 Focal Electroconvulsive Therapy for Depression

Major Depressive Disorder

Primary: Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item. — 5 Participants

Medical University of South Carolina Results Aug 2019 0.0% serious AE View details

N/A N=19 Drug Exposure Registry for GSK2248761, an Investigational NNRTI

HIV Infections

Primary: Number of Participants With Occurrence of Seizure — 0; 1 Participants

ViiV Healthcare Results Sep 2019 5.3% serious AE View details

N/A N=100 Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer

Prostate Cancer · Non-metastatic Prostate Cancer · Prostate Adenocarcinoma

Primary: Pilot: Acceptance of Randomisation to Allocated Arm Within CHRONOS A & CHRONOS B — 4; 0; 11; 10 Participants

Imperial College London Results Mar 2025 8.0% serious AE View details

N/A N=30 Penetrating the Classroom Social Network for Children With Language Impairment Via Peer Mediated Intervention

Peer Influence

Primary: Preschool Language Screener 5 (PLS-5) - Growth Scale Value — 437.09; 455.38; 459.09; 464.77 score on a scale — p=.84

Ohio State University Results Jan 2025 0.0% serious AE View details

Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures

Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants

Eisai Inc. Results May 2022 7.4% serious AE View details

Phase 3 N=20 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).

Photosensitive Epilepsy

Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001

Elizabeth Anne Thiele Results Feb 2023 0.0% serious AE View details

Phase 3 N=234 Efficacy and Safety of Primovist in Chinese Patients

Known or Suspected Focal Liver Lesions

Primary: Difference in Sensitivity of Lesion Detection in MRI Images (Post-contrast MRI Minus Pre-contrast MRI) Measured as Percentage Points — 8.65; 12.23; 7.50 Percentage points

Bayer Results Dec 2009 0.0% serious AE View details

Phase 2 N=411 Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

Drug-resistant Epilepsy · Focal-Onset Seizures

Primary: Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period — -0.27585; -0.46424; -0.48804; -0.48960 loge…

UCB Biopharma S.P.R.L. Results Apr 2021 3.0% serious AE View details

Phase 3 N=605 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…

Pfizer's Upjohn has merged with Mylan to form… Results Feb 2020 12.7% serious AE View details

Phase 3 N=180 Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…

Eisai Inc. Results Apr 2020 19.8% serious AE View details

Phase 4 N=106 Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Primary: 50 Percent (%) Responder Rate for Partial Onset Seizure With or Without Secondary Generalization — 80.0 percentage of participants

Eisai Korea Inc. Results Feb 2020 7.8% serious AE View details

Phase 2 N=67 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

Epilepsy, Focal Seizures, Partial Seizures

Primary: Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment — -0.43; -0.58 log(seizure/28 days) — p=0.5053

Biogen Results Apr 2021 5.5% serious AE View details

Phase 3 N=768 Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures